<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Microembolic signals (<z:chebi fb="28" ids="39005,39010">MES</z:chebi>) as detected by transcranial Doppler ultrasound define an individual <z:hpo ids='HP_0001297'>stroke</z:hpo> risk in patients with <z:e sem="disease" ids="C0007273" disease_type="Disease or Syndrome" abbrv="">carotid artery disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To study the composition of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> in vivo, we used the <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa (GPIIb/IIIa) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="9605">tirofiban</z:chebi>, a highly selective <z:chebi fb="0" ids="50427">platelet aggregation inhibitor</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Twenty-four patients with recent cerebral or <z:chebi fb="46" ids="15035">retinal</z:chebi> embolism of arterial origin and a <z:chebi fb="28" ids="39005,39010">MES</z:chebi> rate &gt;6 per hour on initial transcranial Doppler ultrasonography recording received the short-acting GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="9605">tirofiban</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>With <z:chebi fb="0" ids="9605">tirofiban</z:chebi>, the <z:chebi fb="28" ids="39005,39010">MES</z:chebi> rate dropped from a median (range) of 38 (9 to 324) to zero in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>After cessation of infusion, the inhibitory effect of <z:chebi fb="0" ids="9605">tirofiban</z:chebi> was reversible, with a significant increase of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> (median 13.5; range, 0 to 35; n=16; P=0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Six patients received overlapping oral antiplatelet agents and remained <z:chebi fb="28" ids="39005,39010">MES</z:chebi>-negative </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Cerebral microembolism of arterial origin has the property of solid emboli, with platelet-fibrinogen units as predominant constituent parts </plain></SENT>
<SENT sid="7" pm="."><plain>GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonists</z:chebi> may have the potential to bridge the ischemic risk in patients with unstable <z:e sem="disease" ids="C0741975" disease_type="Disease or Syndrome" abbrv="">carotid disease</z:e> </plain></SENT>
</text></document>